Study Details

Open

Tumor Subtypes in Subjects on FOLFIRINOX with Non-Metastatic Pancreatic Cancer

This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina

What will be asked of you

During screening you will receive an imaging scan, blood tests, and an EUS-guided core biopsy. During study treatment, you will receive blood tests, imaging scans, an EUS-guided core biopsy, chemo (FOLFIRINOX), and surgical resection.

Incentives

You will be paid $100 after each EUS-guided core biopsy visit.

In-person visits:
Up to twenty.

Total length of participation:
Up to three years.

Looking for Specific Volunteers

Able to participate:

Participant mush have pancreatic cancer that has not spread (no metastatic disease)
Participants must be willing to undergo a biopsy of their pancreatic cancer both before and after treatment.
Participant must be scheduled to receive the chemo treatment called FOLFIRINOX
Participant must not receive any prior treatment for pancreatic cancer

Not eligible if:

Participant has had any other cancers within the past five years (with some expectations).
Participant is hypersensitive to any of the components of the chemo treatment FOLFIRINOX.
Participant participated in any other research study within four weeks of treatment.
Participant had any major surgery, open biopsy or traumatic injury within four weeks of starting treatment.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Ashwin Somasundaram
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pancreatic)

IRB Number

19-0694

ClinicalTrials.gov

NCT03977233